S&P 500   4,966.64 (-0.18%)
DOW   38,527.79 (-0.09%)
QQQ   423.92 (-0.80%)
AAPL   181.36 (-0.11%)
MSFT   399.54 (-0.81%)
META   467.62 (-0.77%)
GOOGL   142.34 (+0.86%)
AMZN   168.27 (+0.71%)
TSLA   194.25 (+0.25%)
NVDA   671.66 (-3.29%)
NIO   6.06 (+1.68%)
AMD   163.55 (-1.29%)
BABA   75.66 (+3.45%)
T   16.95 (+0.24%)
F   12.12 (-1.06%)
MU   80.57 (-0.17%)
CGC   3.39 (-4.24%)
GE   148.28 (-0.23%)
DIS   107.85 (-1.45%)
AMC   4.55 (-2.36%)
PFE   27.51 (-0.29%)
PYPL   57.57 (-1.81%)
XOM   104.87 (+2.06%)
S&P 500   4,966.64 (-0.18%)
DOW   38,527.79 (-0.09%)
QQQ   423.92 (-0.80%)
AAPL   181.36 (-0.11%)
MSFT   399.54 (-0.81%)
META   467.62 (-0.77%)
GOOGL   142.34 (+0.86%)
AMZN   168.27 (+0.71%)
TSLA   194.25 (+0.25%)
NVDA   671.66 (-3.29%)
NIO   6.06 (+1.68%)
AMD   163.55 (-1.29%)
BABA   75.66 (+3.45%)
T   16.95 (+0.24%)
F   12.12 (-1.06%)
MU   80.57 (-0.17%)
CGC   3.39 (-4.24%)
GE   148.28 (-0.23%)
DIS   107.85 (-1.45%)
AMC   4.55 (-2.36%)
PFE   27.51 (-0.29%)
PYPL   57.57 (-1.81%)
XOM   104.87 (+2.06%)
S&P 500   4,966.64 (-0.18%)
DOW   38,527.79 (-0.09%)
QQQ   423.92 (-0.80%)
AAPL   181.36 (-0.11%)
MSFT   399.54 (-0.81%)
META   467.62 (-0.77%)
GOOGL   142.34 (+0.86%)
AMZN   168.27 (+0.71%)
TSLA   194.25 (+0.25%)
NVDA   671.66 (-3.29%)
NIO   6.06 (+1.68%)
AMD   163.55 (-1.29%)
BABA   75.66 (+3.45%)
T   16.95 (+0.24%)
F   12.12 (-1.06%)
MU   80.57 (-0.17%)
CGC   3.39 (-4.24%)
GE   148.28 (-0.23%)
DIS   107.85 (-1.45%)
AMC   4.55 (-2.36%)
PFE   27.51 (-0.29%)
PYPL   57.57 (-1.81%)
XOM   104.87 (+2.06%)
S&P 500   4,966.64 (-0.18%)
DOW   38,527.79 (-0.09%)
QQQ   423.92 (-0.80%)
AAPL   181.36 (-0.11%)
MSFT   399.54 (-0.81%)
META   467.62 (-0.77%)
GOOGL   142.34 (+0.86%)
AMZN   168.27 (+0.71%)
TSLA   194.25 (+0.25%)
NVDA   671.66 (-3.29%)
NIO   6.06 (+1.68%)
AMD   163.55 (-1.29%)
BABA   75.66 (+3.45%)
T   16.95 (+0.24%)
F   12.12 (-1.06%)
MU   80.57 (-0.17%)
CGC   3.39 (-4.24%)
GE   148.28 (-0.23%)
DIS   107.85 (-1.45%)
AMC   4.55 (-2.36%)
PFE   27.51 (-0.29%)
PYPL   57.57 (-1.81%)
XOM   104.87 (+2.06%)
NASDAQ:CVRX

CVRx (CVRX) Stock Price, News & Analysis

$21.36
-0.88 (-3.96%)
(As of 01:52 PM ET)
Today's Range
$21.28
$22.20
50-Day Range
$22.24
$33.01
52-Week Range
$7.26
$33.13
Volume
55,492 shs
Average Volume
159,366 shs
Market Capitalization
$447.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.67

CVRx MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
57.6% Upside
$33.67 Price Target
Short Interest
Healthy
4.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of CVRx in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.89) to ($1.53) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.74 out of 5 stars

Medical Sector

659th out of 932 stocks

Surgical & Medical Instruments Industry

74th out of 95 stocks


CVRX stock logo

About CVRx Stock (NASDAQ:CVRX)

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CVRX Stock Price History

CVRX Stock News Headlines

CVRX Mar 2024 30.000 call
CVRX Mar 2024 20.000 put
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
CVRx names Kevin Hykes as CEO
Piper Sandler Keeps Their Buy Rating on CVRx (CVRX)
CVRx Full Year 2023 Earnings: EPS Beats Expectations
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
CVRx Names Board Member Kevin Hykes President, CEO
Bio-Techne (TECH) Receives a Buy from Craig-Hallum
CVRx, Inc. (NASDAQ:CVRX) Q4 2023 Earnings Call Transcript
Q4 2023 CVRx Inc Earnings Call
CVRx: Q4 Earnings Insights
Earnings Outlook For CVRx
What Makes CVRx (CVRX) a Good Fit for 'Trend Investing'
Craig-Hallum Keeps Their Buy Rating on CVRx (CVRX)
See More Headlines
Receive CVRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CVRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/25/2024
Today
2/21/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:CVRX
Employees
200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.67
High Stock Price Target
$36.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+51.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-41,200,000.00
Net Margins
-104.85%
Pretax Margin
-104.47%

Debt

Sales & Book Value

Annual Sales
$39.29 million
Book Value
$3.63 per share

Miscellaneous

Free Float
17,098,000
Market Cap
$465.48 million
Optionable
Optionable
Beta
1.50
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Kevin Hykes (Age 58)
    President, CEO & Director
  • Mr. Jared Oasheim (Age 40)
    Chief Financial Officer
    Comp: $446.1k
  • Mr. Paul Verrastro (Age 61)
    Chief Marketing & Strategy Officer
    Comp: $529.84k
  • Mr. Paul Pignato
    Vice President of Operations
  • Ms. Jonelle R. Burnham (Age 53)
    Vice President & General Counsel
  • Mr. Craig Palmer (Age 47)
    Senior Vice President of US Sales














CVRX Stock Analysis - Frequently Asked Questions

Should I buy or sell CVRx stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CVRx in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CVRX shares.
View CVRX analyst ratings
or view top-rated stocks.

What is CVRx's stock price target for 2024?

3 analysts have issued 1-year price targets for CVRx's shares. Their CVRX share price targets range from $32.00 to $36.00. On average, they expect the company's share price to reach $33.67 in the next year. This suggests a possible upside of 57.6% from the stock's current price.
View analysts price targets for CVRX
or view top-rated stocks among Wall Street analysts.

How have CVRX shares performed in 2024?

CVRx's stock was trading at $31.44 on January 1st, 2024. Since then, CVRX shares have decreased by 32.1% and is now trading at $21.36.
View the best growth stocks for 2024 here
.

Are investors shorting CVRx?

CVRx saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 479,500 shares, an increase of 32.3% from the January 15th total of 362,300 shares. Based on an average trading volume of 159,400 shares, the short-interest ratio is currently 3.0 days. Currently, 4.9% of the shares of the company are sold short.
View CVRx's Short Interest
.

When is CVRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our CVRX earnings forecast
.

How were CVRx's earnings last quarter?

CVRx, Inc. (NASDAQ:CVRX) posted its quarterly earnings results on Thursday, January, 25th. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.11. The company had revenue of $11.31 million for the quarter, compared to the consensus estimate of $10.90 million. CVRx had a negative net margin of 104.85% and a negative trailing twelve-month return on equity of 47.30%.

What guidance has CVRx issued on next quarter's earnings?

CVRx issued an update on its first quarter 2024 earnings guidance on Friday, January, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11.0 million-$12.0 million, compared to the consensus revenue estimate of $11.6 million.

When did CVRx IPO?

(CVRX) raised $100 million in an IPO on Wednesday, June 30th 2021. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share.

Who are CVRx's major shareholders?

CVRx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.69%), Balyasny Asset Management L.P. (1.94%), Parkman Healthcare Partners LLC (1.15%), Northern Trust Corp (0.46%), Mairs & Power Inc. (0.44%) and Cresset Asset Management LLC (0.16%). Insiders that own company stock include Kirk G Nielsen, Mudit K Jain, Nea Partners 10 L P and Paul Verrastro.
View institutional ownership trends
.

How do I buy shares of CVRx?

Shares of CVRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CVRX) was last updated on 2/21/2024 by MarketBeat.com Staff